Neglected Tropical Disease (NTD) Treatment Market
Neglected Tropical Disease (NTD) Treatment Market Size, Share & Trends Analysis Report, By Disease Type (Lymphatic Filariasis, Onchocerciasis (River Blindness), Schistosomiasis, Soil-Transmitted Helminthiasis, Leishmaniasis, Chagas Disease, Human African Trypanosomiasis (Sleeping Sickness), Dengue & Arboviral Infections, Leprosy, Trachoma, Buruli Ulcer, Other Neglected Tropical Diseases), By Treatment Modality (Oral Therapies, Injectable Therapies, Topical Therapies, Vector-Control Integrated Therapeutics), By End User (Hospitals, Infectious Disease Clinics, Community Healthcare Centers, Public Health Programs, Research Institutes & Academic Centers), Forecast Period (2026-2035)
Industry Overview
Neglected Tropical Disease (NTD) treatment market size was valued at $3.61 billion in 2025 and is projected to reach $6.46 billion by 2035, growing at a CAGR of 6.0% between 2026 and 2035. The market includes therapeutics and disease management solutions used for infectious and parasitic diseases affecting populations primarily in tropical and subtropical regions. A key factor supporting market growth is the increasing burden of vector-borne and parasitic diseases globally. According to the World Health Organization (WHO), more than 1 billion people globally are affected by neglected tropical diseases, particularly across low-income regions lacking adequate sanitation and healthcare access. Increasing government-supported disease elimination initiatives, growing awareness regarding infectious disease management, and rising investments in vaccine development are accelerating market expansion. Pharmaceutical companies are strengthening collaborations with public health organizations between 2024 and 2026 to improve treatment accessibility. Hospitals and public health programs remain the dominant end users due to large-scale disease control initiatives and expanding healthcare infrastructure globally.
Market Dynamics
Rising Burden of Infectious Diseases Driving Market Growth
The increasing prevalence of infectious and vector-borne diseases is a major factor driving market growth. According to the World Health Organization, dengue cases increased significantly worldwide, with more than 14 million reported cases globally in 2024. Rapid urbanization, climate change, poor sanitation conditions, and expansion of mosquito vectors are accelerating the spread of neglected tropical diseases. Governments and healthcare organizations are expanding preventive chemotherapy and vaccination programs to strengthen disease elimination initiatives. Pharmaceutical manufacturers are increasing investments in infectious disease therapeutics and vaccine innovation between 2024 and 2026 to improve treatment outcomes and strengthen product accessibility. Rising collaboration between pharmaceutical companies and global healthcare organizations is further supporting market growth and enhancing disease management capabilities globally.
Limited Healthcare Infrastructure and High Development Costs Limiting Market Growth
Despite strong growth potential, the neglected tropical disease treatment market faces challenges related to limited healthcare infrastructure and high development costs. Many endemic countries continue to experience inadequate healthcare accessibility and limited diagnostic capabilities, restricting timely treatment adoption. Development of vaccines, biologics, and advanced therapeutics requires substantial investment and extended regulatory approval timelines. Low commercial profitability associated with neglected tropical diseases further discourages private sector investment. Pharmaceutical companies and public health organizations are addressing these challenges through strategic partnerships, funding programs, and expanded manufacturing initiatives. Increasing support from global health agencies is helping improve treatment affordability and strengthen infectious disease control programs.
Market Segmentation
- Based on the disease type, the market is segmented into lymphatic filariasis, onchocerciasis (river blindness), schistosomiasis, soil-transmitted helminthiasis, leishmaniasis, Chagas disease, human African trypanosomiasis (sleeping sickness), dengue & arboviral infections, leprosy, trachoma, buruli ulcer, and other neglected tropical diseases.
- Based on the treatment modality, the market is segmented into oral therapies, injectable therapies, topical therapies, and vector-control integrated therapeutics.
- Based on the end user, the market is segmented into hospitals, infectious disease clinics, community healthcare centers, public health programs, and research institutes & academic centers.
Oral Therapies Segment Leads the Market
The oral therapies segment holds a dominant position due to its widespread adoption in preventive chemotherapy and mass drug administration programs. Oral antiparasitic therapies are cost-effective and suitable for large-scale infectious disease management campaigns. Governments and global healthcare organizations have increased procurement of oral drugs between 2022 and 2026 to strengthen disease elimination initiatives across Asia-Pacific and Africa. Pharmaceutical manufacturers are expanding generic drug production and strengthening supply chains to improve treatment accessibility. WHO-backed eradication initiatives for lymphatic filariasis and soil-transmitted helminthiasis continue to support strong demand for oral therapies globally.
Vector-Control Integrated Therapeutics Segment to Record Strong Growth
The vector-control integrated therapeutics segment is expected to witness strong growth due to increasing investments in mosquito-borne disease prevention technologies and integrated disease management systems. Rising prevalence of dengue and arboviral infections is accelerating demand for combined therapeutics and vector-control strategies. Governments and healthcare organizations are investing in advanced mosquito surveillance programs and vaccine development initiatives to reduce disease transmission. Pharmaceutical and biotechnology companies are expanding research activities related to biologics, vaccines, and integrated infectious disease control technologies between 2024 and 2026. Growing focus on climate-sensitive infectious disease prevention is further supporting segment growth.
Regional Outlook
The global Neglected Tropical Disease (NTD) Treatment market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).
India Leads the Market
India dominates the neglected tropical disease treatment market due to the high prevalence of dengue, lymphatic filariasis, and parasitic infections. According to the World Health Organization, India has implemented one of the world’s largest mass drug administration programs targeting lymphatic filariasis elimination. Government-backed disease eradication initiatives, expanding pharmaceutical manufacturing capabilities, and increasing healthcare accessibility are strengthening market growth. Rising public awareness regarding infectious disease management and growing investments in healthcare infrastructure are further supporting adoption of NTD treatment solutions across the country.
China to Record Strong Growth
China is expected to witness strong growth due to increasing investments in infectious disease surveillance and public healthcare modernization. According to the World Health Organization, China has strengthened vector-borne disease prevention and monitoring programs in recent years. Rising healthcare expenditure, improving pharmaceutical manufacturing infrastructure, and increasing focus on vaccine development are supporting market expansion. Government initiatives aimed at strengthening infectious disease preparedness and increasing collaboration with international healthcare organizations are further driving adoption of advanced NTD treatment solutions.
Competitive Landscape
The neglected tropical disease treatment market is highly competitive, with companies focusing on strategic collaborations, infectious disease research, and vaccine innovation. Key players such as Takeda Pharmaceutical Company Limited, Sanofi S.A., Bayer AG, GlaxoSmithKline plc, and Knight Therapeutics Inc. are investing in biologics, antiparasitic therapeutics, and mosquito-borne disease prevention technologies to strengthen their market presence. These companies are expanding partnerships with governments and global health organizations to improve treatment accessibility and strengthen disease elimination initiatives globally.
Recent Developments
- In March 2026, Bayer AG announced that it achieved its upgraded 2025 financial targets and projected stable sales and earnings growth for 2026, supported by strategic priorities across its Pharmaceuticals, Crop Science, and Consumer Health divisions. The company highlighted expansion of its pharmaceutical growth drivers, continued pipeline advancement, and implementation of its Dynamic Shared Ownership operating model to improve operational efficiency and strengthen long-term profitability.
- In January 2026, Bayer AG announced acceleration of its pharmaceutical growth strategy through expansion of its high-value portfolio across oncology, cardiology, neurology, and immunology. The company highlighted five pivotal approvals achieved in 2025, multiple global regulatory expansion plans, and advancement of its modality-rich pipeline to strengthen long-term growth and market competitiveness in the pharmaceutical sector.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global neglected tropical disease (NTD) treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Neglected Tropical Disease (NTD) Treatment Market Sales Analysis – Disease Type | Treatment Modality | End User ($ Million)
- Neglected Tropical Disease (NTD) Treatment Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
2.1 Scope of the Study
2.2 Analyst Insight & Current Market Trends
2.2.1 Key Neglected Tropical Disease (NTD) Treatment Market Trends
2.2.2 Market Recommendations
2.3 Porter's Five Forces Analysis for the Neglected Tropical Disease (NTD) Treatment Market
2.3.1 Competitive Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes
- Market Determinants
3.1 Market Drivers
3.1.1 Drivers For Global Neglected Tropical Disease (NTD) Treatment Market: Impact Analysis
3.2 Market Pain Points and Challenges
3.2.1 Restraints For Global Neglected Tropical Disease (NTD) Treatment Market: Impact Analysis
3.3 Market Opportunities
3.3.1 Opportunities For Global Neglected Tropical Disease (NTD) Treatment Market: Impact Analysis
- Competitive Landscape
4.1 Competitive Dashboard – Neglected Tropical Disease (NTD) Treatment Market Revenue and Share by Manufacturers
- Neglected Tropical Disease (NTD) Treatment Product Comparison Analysis
- Top Market Player Ranking Matrix
4.2 Key Company Analysis
4.2.1 Takeda Pharmaceutical Company Limited
4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy
4.2.2 Sanofi S.A.
4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy
4.2.3 Bayer AG
4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy
4.2.4 GlaxoSmithKline plc
4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy
4.2.5 Knight Therapeutics Inc.
4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy
4.3 Top Winning Strategies by Market Players
4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership And Collaboration
- Global Neglected Tropical Disease (NTD) Treatment Market Sales Analysis by Disease Type ($ Million)
5.1 Lymphatic Filariasis
5.2 Onchocerciasis (River Blindness)
5.3 Schistosomiasis
5.4 Soil-Transmitted Helminthiasis
5.5 Leishmaniasis
5.6 Chagas Disease
5.7 Human African Trypanosomiasis (Sleeping Sickness)
5.8 Dengue & Arboviral Infections
5.9 Leprosy
5.10 Trachoma
5.11 Buruli Ulcer
5.12 Other Neglected Tropical Diseases
- Global Neglected Tropical Disease (NTD) Treatment Market Sales Analysis by Treatment Modality ($ Million)
6.1 Oral Therapies
6.2 Injectable Therapies
6.3 Topical Therapies
6.4 Vector-Control Integrated Therapeutics
- Global Neglected Tropical Disease (NTD) Treatment Market Sales Analysis by End User ($ Million)
7.1 Hospitals
7.2 Infectious Disease Clinics
7.3 Community Healthcare Centers
7.4 Public Health Programs
7.5 Research Institutes & Academic Centers
- Regional Analysis
8.1 North American Neglected Tropical Disease (NTD) Treatment Market Sales Analysis – Disease Type | Treatment Modality | End User ($ Million)
8.1.1 United States
8.1.2 Canada
8.2 European Neglected Tropical Disease (NTD) Treatment Market Sales Analysis – Disease Type | Treatment Modality | End User ($ Million)
8.2.1 UK
8.2.2 Germany
8.2.3 Italy
8.2.4 Spain
8.2.5 France
8.2.6 Russia
8.2.7 Rest of Europe
8.3 Asia-Pacific Neglected Tropical Disease (NTD) Treatment Market Sales Analysis – Disease Type | Treatment Modality | End User ($ Million)
8.3.1 China
8.3.2 Japan
8.3.3 South Korea
8.3.4 India
8.3.5 Australia & New Zealand
8.3.6 ASEAN Countries
8.3.7 Rest of Asia-Pacific
8.4 Rest of the World Neglected Tropical Disease (NTD) Treatment Market Sales Analysis – Disease Type | Treatment Modality | End User ($ Million)
8.4.1 Latin America
8.4.2 Middle East and Africa
- Company Profiles
9.1 Ajanta Pharma Limited
9.1.1 Quick Facts
9.1.2 Company Overview
9.1.3 Product Portfolio
9.1.4 Business Strategies
9.2 Alkem Laboratories Ltd.
9.2.1 Quick Facts
9.2.2 Company Overview
9.2.3 Product Portfolio
9.2.4 Business Strategies
9.3 AstraZeneca plc
9.3.1 Quick Facts
9.3.2 Company Overview
9.3.3 Product Portfolio
9.3.4 Business Strategies
9.4 Aurobindo Pharma Limited
9.4.1 Quick Facts
9.4.2 Company Overview
9.4.3 Product Portfolio
9.4.4 Business Strategies
9.5 Biological E. Limited
9.5.1 Quick Facts
9.5.2 Company Overview
9.5.3 Product Portfolio
9.5.4 Business Strategies
9.6 Cipla Ltd.
9.6.1 Quick Facts
9.6.2 Company Overview
9.6.3 Product Portfolio
9.6.4 Business Strategies
9.7 Eisai Co., Ltd.
9.7.1 Quick Facts
9.7.2 Company Overview
9.7.3 Product Portfolio
9.7.4 Business Strategies
9.8 Glenmark Pharmaceuticals Ltd.
9.8.1 Quick Facts
9.8.2 Company Overview
9.8.3 Product Portfolio
9.8.4 Business Strategies
9.9 Hetero Drugs Limited
9.9.1 Quick Facts
9.9.2 Company Overview
9.9.3 Product Portfolio
9.9.4 Business Strategies
9.10 Ipca Laboratories Ltd.
9.10.1 Quick Facts
9.10.2 Company Overview
9.10.3 Product Portfolio
9.10.4 Business Strategies
9.11 Johnson & Johnson
9.11.1 Quick Facts
9.11.2 Company Overview
9.11.3 Product Portfolio
9.11.4 Business Strategies
9.12 Lupin Limited
9.12.1 Quick Facts
9.12.2 Company Overview
9.12.3 Product Portfolio
9.12.4 Business Strategies
9.13 MacLeods Pharmaceuticals Ltd.
9.13.1 Quick Facts
9.13.2 Company Overview
9.13.3 Product Portfolio
9.13.4 Business Strategies
9.14 Merck KGaA
9.14.1 Quick Facts
9.14.2 Company Overview
9.14.3 Product Portfolio
9.14.4 Business Strategies
9.15 Novartis AG
9.15.1 Quick Facts
9.15.2 Company Overview
9.15.3 Product Portfolio
9.15.4 Business Strategies
9.16 Pfizer Inc.
9.16.1 Quick Facts
9.16.2 Company Overview
9.16.3 Product Portfolio
9.16.4 Business Strategies
9.17 Strides Pharma Science Limited
9.17.1 Quick Facts
9.17.2 Company Overview
9.17.3 Product Portfolio
9.17.4 Business Strategies
9.18 Sun Pharmaceutical Industries Ltd.
9.18.1 Quick Facts
9.18.2 Company Overview
9.18.3 Product Portfolio
9.18.4 Business Strategies
9.19 Viatris Inc.
9.19.1 Quick Facts
9.19.2 Company Overview
9.19.3 Product Portfolio
9.19.4 Business Strategies
9.20 Zydus Lifesciences Limited
9.20.1 Quick Facts
9.20.2 Company Overview
9.20.3 Product Portfolio
9.20.4 Business Strategies
1. Global Neglected Tropical Disease (NTD) Treatment Market Research and Analysis by Disease Type, 2026–2035 ($ Million)
2. Global Lymphatic Filariasis Market Research and Analysis by Region, 2026–2035 ($ Million)
3. Global Onchocerciasis (River Blindness) Market Research and Analysis by Region, 2026–2035 ($ Million)
4. Global Schistosomiasis Market Research and Analysis by Region, 2026–2035 ($ Million)
5. Global Soil-Transmitted Helminthiasis Market Research and Analysis by Region, 2026–2035 ($ Million)
6. Global Leishmaniasis Market Research and Analysis by Region, 2026–2035 ($ Million)
7. Global Chagas Disease Market Research and Analysis by Region, 2026–2035 ($ Million)
8. Global Human African Trypanosomiasis (Sleeping Sickness) Market Research and Analysis by Region, 2026–2035 ($ Million)
9. Global Dengue & Arboviral Infections Market Research and Analysis by Region, 2026–2035 ($ Million)
10. Global Leprosy Market Research and Analysis by Region, 2026–2035 ($ Million)
11. Global Trachoma Market Research and Analysis by Region, 2026–2035 ($ Million)
12. Global Buruli Ulcer Market Research and Analysis by Region, 2026–2035 ($ Million)
13. Global Other Neglected Tropical Diseases Market Research and Analysis by Region, 2026–2035 ($ Million)
14. Global Neglected Tropical Disease (NTD) Treatment Market Research and Analysis by Treatment Modality, 2026–2035 ($ Million)
15. Global Oral Therapies Market Research and Analysis by Region, 2026–2035 ($ Million)
16. Global Injectable Therapies Market Research and Analysis by Region, 2026–2035 ($ Million)
17. Global Topical Therapies Market Research and Analysis by Region, 2026–2035 ($ Million)
18. Global Vector-Control Integrated Therapeutics Market Research and Analysis by Region, 2026–2035 ($ Million)
19. Global Neglected Tropical Disease (NTD) Treatment Market Research and Analysis by End User, 2026–2035 ($ Million)
20. Global Neglected Tropical Disease (NTD) Treatment Market for Hospitals Research and Analysis by Region, 2026–2035 ($ Million)
21. Global Neglected Tropical Disease (NTD) Treatment Market for Infectious Disease Clinics Research and Analysis by Region, 2026–2035 ($ Million)
22. Global Neglected Tropical Disease (NTD) Treatment Market for Community Healthcare Centers Research and Analysis by Region, 2026–2035 ($ Million)
23. Global Neglected Tropical Disease (NTD) Treatment Market for Public Health Programs Research and Analysis by Region, 2026–2035 ($ Million)
24. Global Neglected Tropical Disease (NTD) Treatment Market for Research Institutes & Academic Centers Research and Analysis by Region, 2026–2035 ($ Million)
25. Global Neglected Tropical Disease (NTD) Treatment Market Research and Analysis by Region, 2026–2035 ($ Million)
26. North America Neglected Tropical Disease (NTD) Treatment Market Research and Analysis by Country, 2026–2035 ($ Million)
27. North America Neglected Tropical Disease (NTD) Treatment Market Research and Analysis by Disease Type, 2026–2035 ($ Million)
28. North America Neglected Tropical Disease (NTD) Treatment Market Research and Analysis by Treatment Modality, 2026–2035 ($ Million)
29. North America Neglected Tropical Disease (NTD) Treatment Market Research and Analysis by End User, 2026–2035 ($ Million)
30. Europe Neglected Tropical Disease (NTD) Treatment Market Research and Analysis by Country, 2026–2035 ($ Million)
31. Europe Neglected Tropical Disease (NTD) Treatment Market Research and Analysis by Disease Type, 2026–2035 ($ Million)
32. Europe Neglected Tropical Disease (NTD) Treatment Market Research and Analysis by Treatment Modality, 2026–2035 ($ Million)
33. Europe Neglected Tropical Disease (NTD) Treatment Market Research and Analysis by End User, 2026–2035 ($ Million)
34. Asia-Pacific Neglected Tropical Disease (NTD) Treatment Market Research and Analysis by Country, 2026–2035 ($ Million)
35. Asia-Pacific Neglected Tropical Disease (NTD) Treatment Market Research and Analysis by Disease Type, 2026–2035 ($ Million)
36. Asia-Pacific Neglected Tropical Disease (NTD) Treatment Market Research and Analysis by Treatment Modality, 2026–2035 ($ Million)
37. Asia-Pacific Neglected Tropical Disease (NTD) Treatment Market Research and Analysis by End User, 2026–2035 ($ Million)
38. Rest of the World Neglected Tropical Disease (NTD) Treatment Market Research and Analysis by Region, 2026–2035 ($ Million)
1. Global Neglected Tropical Disease (NTD) Treatment Market Share by Disease Type, 2026 Vs 2035 (%)
2. Global Lymphatic Filariasis Market Share by Region, 2026 Vs 2035 (%)
3. Global Onchocerciasis (River Blindness) Market Share by Region, 2026 Vs 2035 (%)
4. Global Schistosomiasis Market Share by Region, 2026 Vs 2035 (%)
5. Global Soil-Transmitted Helminthiasis Market Share by Region, 2026 Vs 2035 (%)
6. Global Leishmaniasis Market Share by Region, 2026 Vs 2035 (%)
7. Global Chagas Disease Market Share by Region, 2026 Vs 2035 (%)
8. Global Human African Trypanosomiasis (Sleeping Sickness) Market Share by Region, 2026 Vs 2035 (%)
9. Global Dengue & Arboviral Infections Market Share by Region, 2026 Vs 2035 (%)
10. Global Leprosy Market Share by Region, 2026 Vs 2035 (%)
11. Global Trachoma Market Share by Region, 2026 Vs 2035 (%)
12. Global Buruli Ulcer Market Share by Region, 2026 Vs 2035 (%)
13. Global Other Neglected Tropical Diseases Market Share by Region, 2026 Vs 2035 (%)
14. Global Neglected Tropical Disease (NTD) Treatment Market Share by Treatment Modality, 2026 Vs 2035 (%)
15. Global Oral Therapies Market Share by Region, 2026 Vs 2035 (%)
16. Global Injectable Therapies Market Share by Region, 2026 Vs 2035 (%)
17. Global Topical Therapies Market Share by Region, 2026 Vs 2035 (%)
18. Global Vector-Control Integrated Therapeutics Market Share by Region, 2026 Vs 2035 (%)
19. Global Neglected Tropical Disease (NTD) Treatment Market Share by End User, 2026 Vs 2035 (%)
20. Global Neglected Tropical Disease (NTD) Treatment Market for Hospitals Share by Region, 2026 Vs 2035 (%)
21. Global Neglected Tropical Disease (NTD) Treatment Market for Infectious Disease Clinics Share by Region, 2026 Vs 2035 (%)
22. Global Neglected Tropical Disease (NTD) Treatment Market for Community Healthcare Centers Share by Region, 2026 Vs 2035 (%)
23. Global Neglected Tropical Disease (NTD) Treatment Market for Public Health Programs Share by Region, 2026 Vs 2035 (%)
24. Global Neglected Tropical Disease (NTD) Treatment Market for Research Institutes & Academic Centers Share by Region, 2026 Vs 2035 (%)
25. Global Neglected Tropical Disease (NTD) Treatment Market Share by Region, 2026 Vs 2035 (%)
26. US Neglected Tropical Disease (NTD) Treatment Market Size, 2026–2035 ($ Million)
27. Canada Neglected Tropical Disease (NTD) Treatment Market Size, 2026–2035 ($ Million)
28. UK Neglected Tropical Disease (NTD) Treatment Market Size, 2026–2035 ($ Million)
29. France Neglected Tropical Disease (NTD) Treatment Market Size, 2026–2035 ($ Million)
30. Germany Neglected Tropical Disease (NTD) Treatment Market Size, 2026–2035 ($ Million)
31. Italy Neglected Tropical Disease (NTD) Treatment Market Size, 2026–2035 ($ Million)
32. Spain Neglected Tropical Disease (NTD) Treatment Market Size, 2026–2035 ($ Million)
33. Russia Neglected Tropical Disease (NTD) Treatment Market Size, 2026–2035 ($ Million)
34. India Neglected Tropical Disease (NTD) Treatment Market Size, 2026–2035 ($ Million)
35. China Neglected Tropical Disease (NTD) Treatment Market Size, 2026–2035 ($ Million)
36. Japan Neglected Tropical Disease (NTD) Treatment Market Size, 2026–2035 ($ Million)
37. South Korea Neglected Tropical Disease (NTD) Treatment Market Size, 2026–2035 ($ Million)
38. Australia & New Zealand Neglected Tropical Disease (NTD) Treatment Market Size, 2026–2035 ($ Million)
39. ASEAN Neglected Tropical Disease (NTD) Treatment Market Size, 2026–2035 ($ Million)
40. Middle East & Africa Neglected Tropical Disease (NTD) Treatment Market Size, 2026–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
